Pors K - Search Results

1

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K. Sheldrake HM, et al. Among authors: pors k. J Med Chem. 2013 Aug 8;56(15):6273-7. doi: 10.1021/jm4000209. Epub 2013 Jul 26. J Med Chem. 2013. PMID: 23844629 Free article.

2

Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.

Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH. Pors K, et al. J Med Chem. 2004 Mar 25;47(7):1856-9. doi: 10.1021/jm031070u. J Med Chem. 2004. PMID: 15027879

3

Truncated azinomycin analogues intercalate into DNA.

Casely-Hayford MA, Pors K, Patterson LH, Gerner C, Neidle S, Searcey M. Casely-Hayford MA, et al. Among authors: pors k. Bioorg Med Chem Lett. 2005 Feb 1;15(3):653-6. doi: 10.1016/j.bmcl.2004.11.037. Bioorg Med Chem Lett. 2005. PMID: 15664831

4

Design and synthesis of a DNA-crosslinking azinomycin analogue.

Casely-Hayford MA, Pors K, James CH, Patterson LH, Hartley JA, Searcey M. Casely-Hayford MA, et al. Among authors: pors k. Org Biomol Chem. 2005 Oct 7;3(19):3585-9. doi: 10.1039/b508908e. Epub 2005 Sep 5. Org Biomol Chem. 2005. PMID: 16172698

5

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells.

Pors K, Plumb JA, Brown R, Teesdale-Spittle P, Searcey M, Smith PJ, Patterson LH. Pors K, et al. J Med Chem. 2005 Oct 20;48(21):6690-5. doi: 10.1021/jm050438f. J Med Chem. 2005. PMID: 16220985

6

DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents.

Pors K, Patterson LH. Pors K, et al. Curr Top Med Chem. 2005;5(12):1133-49. doi: 10.2174/156802605774370883. Curr Top Med Chem. 2005. PMID: 16248788 Review.

7

Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides.

Pors K, Shnyder SD, Teesdale-Spittle PH, Hartley JA, Zloh M, Searcey M, Patterson LH. Pors K, et al. J Med Chem. 2006 Nov 30;49(24):7013-23. doi: 10.1021/jm0608154. J Med Chem. 2006. PMID: 17125254

8

Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products.

Ghosh N, Sheldrake HM, Searcey M, Pors K. Ghosh N, et al. Among authors: pors k. Curr Top Med Chem. 2009;9(16):1494-524. doi: 10.2174/156802609789909812. Curr Top Med Chem. 2009. PMID: 19903166 Review.

9

Use of the hollow fiber assay for the evaluation of DNA damaging agents.

Veiga JP, Cooper PA, Pors K, Patterson LH, Bibby MC, Shnyder SD. Veiga JP, et al. Among authors: pors k. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. doi: 10.1016/j.vascn.2011.04.006. Epub 2011 Apr 30. J Pharmacol Toxicol Methods. 2011. PMID: 21569858

10

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.

Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH. Pors K, et al. Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14. Chem Commun (Camb). 2011. PMID: 22002321

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page